TRCT
NGNE icon

Tower Research Capital (TRC)’s Neurogene NGNE Stock Holding History

Tower Research Capital (TRC)’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.8K Buy
1,279
+46
+4% +$891 ﹤0.01% 3301
2025
Q4 		$25.4K Buy
1,233
+66
+6% +$1.64K ﹤0.01% 2919
2025
Q3 		$20.2K Sell
1,167
-749
-39% -$15K ﹤0.01% 3298
2025
Q2 		$28.6K Buy
1,916
+1,246
+186% +$19.6K ﹤0.01% 3443
2025
Q1 		$7.85K Buy
670
+41
+7% +$712 ﹤0.01% 3929
2024
Q4 		$14.4K Sell
629
-7,767
-93% -$289K ﹤0.01% 3464
2024
Q3 		$352K Buy
+8,396
New +$326K 0.01% 1117
2023
Q4 		– Sell
-206
Closed -$3.25K – 6087
2023
Q3 		$3.25K Buy
+206
New +$3.04K ﹤0.01% 5030
2023
Q2 		– Sell
-31
Closed – – 6260
2023
Q1 		$0 Sell
31
-157
-84% -$1.84K ﹤0.01% 6128
2022
Q4 		$2K Sell
188
-311
-62% -$3.21K ﹤0.01% 5398
2022
Q3 		$6K Buy
499
+18
+4% +$367 ﹤0.01% 5031
2022
Q2 		$10K Buy
481
+133
+38% +$3.24K ﹤0.01% 4467
2022
Q1 		$13K Sell
348
-9
-3% -$525 ﹤0.01% 3985
2021
Q4 		$35K Buy
357
+145
+68% +$17.7K ﹤0.01% 3087
2021
Q3 		$31K Buy
212
+69
+48% +$10.6K ﹤0.01% 3356
2021
Q2 		$26K Buy
143
+62
+77% +$13.7K ﹤0.01% 3648
2021
Q1 		$20K Sell
81
-28
-26% -$7.16K ﹤0.01% 3884
2020
Q4 		$31K Sell
109
-1,195
-92% -$292K ﹤0.01% 3544
2020
Q3 		$313K Buy
1,304
+1,230
+1,662% +$298K ﹤0.01% 2141
2020
Q2 		$24K Sell
74
-27
-27% -$7.04K ﹤0.01% 3588
2020
Q1 		$23K Buy
+101
New +$20.8K ﹤0.01% 1644
2019
Q4 		– Sell
-395
Closed -$22K – 4104
2019
Q3 		$22K Buy
395
+231
+141% +$14.1K ﹤0.01% 2415
2019
Q2 		$8K Sell
164
-80
-33% -$4.11K ﹤0.01% 2695
2019
Q1 		$13K Buy
244
+37
+18% +$1.87K ﹤0.01% 2531
2018
Q4 		$9K Buy
+207
New +$10.1K ﹤0.01% 2554
2018
Q3 		– Sell
-67
Closed -$4K – 4093
2018
Q2 		$4K Buy
+67
New +$17.5K ﹤0.01% 3149
2018
Q1 		– Sell
-48
Closed -$11K – 3644
2017
Q4 		$11K Buy
+48
New +$11.2K ﹤0.01% 2499
2017
Q3 		– Sell
-15
Closed -$4K – 4033
2017
Q2 		$4K Sell
15
-31
-67% -$8.87K ﹤0.01% 2106
2017
Q1 		$16K Sell
46
-34
-43% -$11.9K ﹤0.01% 1434
2016
Q4 		$26K Sell
80
-376
-82% -$101K ﹤0.01% 1914
2016
Q3 		$122K Buy
+456
New +$91.9K 0.01% 716
2016
Q2 		– Sell
-123
Closed -$19.6K – 4786
2016
Q1 		$21K Buy
+123
New +$23.9K ﹤0.01% 1309
2015
Q4 		– Sell
-186
Closed -$53K – 4854
2015
Q3 		$53K Buy
186
+144
+343% +$33.2K 0.01% 975
2015
Q2 		$6K Buy
42
+3
+8% +$457 ﹤0.01% 3124
2015
Q1 		$6K Sell
39
-13
-25% -$2.64K ﹤0.01% 3148
2014
Q4 		$8K Sell
52
-49
-49% -$6.98K ﹤0.01% 2350
2014
Q3 		$13K Buy
101
+51
+102% +$7.78K ﹤0.01% 2642
2014
Q2 		$9K Buy
+50
New +$9.65K ﹤0.01% 2445

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Tower Research Capital (TRC)'s NGNE Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Neurogene (NGNE) stake by 3.7% in Q1 2026, buying an estimated $891 and bringing the position to 1,279 shares worth $25.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3301.

Tower Research Capital (TRC) first reported a position in NGNE in Q2 2014 and has held it in 38 quarters since. The position peaked at $352K in Q3 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Tower Research Capital (TRC) held 1,279 shares of Neurogene worth $25.8K as of Q1 2026.
  • Tower Research Capital (TRC) bought 46 Neurogene shares in Q1 2026, an estimated $891.
  • Neurogene made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3301 holding.
  • Tower Research Capital (TRC) first reported a position in Neurogene in Q2 2014 and has held it in 38 quarters since.
  • Tower Research Capital (TRC)'s Neurogene position peaked at $352K in Q3 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.